Publications and Presentations
Review Articles - pDCs
- Demoulin, Stéphanie, et al. “Tumor microenvironment converts plasmacytoid dendritic cells into immunosuppressive/tolerogenic cells: insight into the molecular mechanisms.” Journal of leukocyte biology 93.3 (2013): 343-352.
- Di Domizio, Jeremy, Olivier Demaria, and Michel Gilliet. “Plasmacytoid dendritic cells in melanoma: can we revert bad into good?.”Journal of Investigative Dermatology 134.7 (2014): 1797-1800.
- Lombardi, Vincent C., Svetlana F. Khaiboullina, and Albert A. Rizvanov. “Plasmacytoid dendritic cells, a role in neoplastic prevention and progression.” European journal of clinical investigation 45 (2015): 1-8.
Scientific Publications – CpG Oligonucleotides
- Bates, Paula J., et al. “Antiproliferative activity of G-rich oligonucleotides correlates with protein binding.” Journal of Biological Chemistry 274.37 (1999): 26369-26377.
- Zou, Weiping, et al. “Stromal-derived factor-1 in human tumors recruits and alters the function of plasmacytoid precursor dendritic cells.” Nature medicine 7.12 (2001): 1339-1346.
- Krug, Anne, et al. “Toll‐like receptor expression reveals CpG DNA as a unique microbial stimulus for plasmacytoid dendritic cells which synergizes with CD40 ligand to induce high amounts of IL‐12.” European journal of immunology 31.10 (2001): 3026-3037.
- Shen, Weiyin, et al. “Antitumor mechanisms of oligodeoxynucleotides with CpG and polyG motifs in murine prostate cancer cells: decrease of NF-κ B and AP-1 binding activities and induction of apoptosis.” Antisense and Nucleic Acid Drug Development 12.3 (2002): 155-164.
- Hartmann, Evelyn, et al. “Identification and functional analysis of tumor-infiltrating plasmacytoid dendritic cells in head and neck cancer.” Cancer research 63.19 (2003): 6478-6487.
- Rothenfusser, Simon, et al. “CpG-A and CpG-B oligonucleotides differentially enhance human peptide–specific primary and memory CD8+ T-cell responses in vitro.” Blood 103.6 (2004): 2162-2169.
- Peng, Guangyong, et al. “Toll-like receptor 8-mediated reversal of CD4+ regulatory T cell function.” Science 309.5739 (2005): 1380-1384.
- Labidi-Galy, Sana Intidhar, et al. “Quantitative and functional alterations of plasmacytoid dendritic cells contribute to immune tolerance in ovarian cancer.” Cancer research 71.16 (2011): 5423-5434.
- Katsuda, Masahiro, et al. “Comparison of different classes of CpG-ODN in augmenting the generation of human epitope peptide-specific CTLs.” International journal of oncology 39.5 (2011): 1295-1302.
- Sisirak, Vanja, et al. “Impaired IFN-α production by plasmacytoid dendritic cells favors regulatory T-cell expansion that may contribute to breast cancer progression.” Cancer research 72.20 (2012): 5188-5197.
- Conrad, Curdin, et al. “Plasmacytoid dendritic cells promote immunosuppression in ovarian cancer via ICOS costimulation of Foxp3+ T-regulatory cells.” Cancer research 72.20 (2012): 5240-5249.
- Faget, Julien, et al. “ICOS-ligand expression on plasmacytoid dendritic cells supports breast cancer progression by promoting the accumulation of immunosuppressive CD4+ T cells.” Cancer research 72.23 (2012): 6130-6141.
- ASCO 2016. Milhem, Mohammed, et al. Phase Ib trial of the CpG-A Oligonucleotide CMP-001 combined with pembrolizumab (Pembro) in patients with advanced melanoma. J Clin Oncol 34: Abstract TPS9593.
- ASH 2016. Lemke, Caitlin, et al. Combination lymphoma immunotherapy using checkpoint blockade and intratumoral virus-like particles containing CpG TLR9 agonist. Blood 128(22): Abstract 3023.
- AACR 2017. Bichat, Francis, et al. Antitumor activity of CMP-001 (TLR9 agonist) alone or combined with immune modulators in syngeneic tumor models. 77(13 Suppl): Abstract 2669.
- AACR 2018. Milhem, Mohammed, et al. Intratumoral toll-like receptor 9 (TLR9) agonist, CMP-001, in combination with pembrolizumab can reverse resistance to PD-1 inhibition in a phase Ib trial in subjects with advanced melanoma. 78(13 Suppl): Abstract CT144.
- ASCO 2018. Massa, Ryan, et al. Relationship between pre-treatment organ-specific tumor burden (TB) and response to immunotherapy in advanced melanoma (MEL). 36(15 Suppl): e21507.
- AACR 2019. Miller, Ann, et al. CMP-001, a virus-like particle containing immunostimulatory CpG-A, for treatment of peritoneal carcinomatosis of gastrointestinal and pancreatic cancers. 79(13 Suppl): Abstract 3273.
- SITC 2019. Davar, Diwakar, et al. Phase II trial of neoadjuvant nivolumab (nivo) and intra-tumoral (IT) CMP-001 in high risk resectable melanoma (MEL): preliminary results. Abstract 11648/034.
- SITC 2019. Kirkwood, John, et al. Durable responses in anti-PD-1 refractory melanoma following intra-tumoral injection of a Toll-like receptor 9 (TLR9) agonist, CMP-001, in combination with pembrolizumab. Abstract 11548/085.